Yonhap Infomax NewsHanmi Pharmaceutical Co. is set to maintain double-digit ROE through next year, driven by a 97% proprietary drug portfolio, robust subsidiary performance, and stable financials, though regulatory risks remain.
#YonhapInfomax
#HanmiPharmaceutical #ROE #ProprietaryDrugs #OperatingProfit #FinancialStructure
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103716
#YonhapInfomax
#HanmiPharmaceutical #ROE #ProprietaryDrugs #OperatingProfit #FinancialStructure
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103716
Hanmi Pharmaceutical Maintains Double-Digit ROE—Will Capital Efficiency Excellence Continue Through Next Year
Hanmi Pharmaceutical Co. is set to maintain double-digit ROE through next year, driven by a 97% proprietary drug portfolio, robust subsidiary performance, and stable financials, though regulatory risks remain.